These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 688226)
1. Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids. Badger AM; Buehler RJ; Cooperband SR Cancer Res; 1978 Oct; 38(10):3365-70. PubMed ID: 688226 [TBL] [Abstract][Full Text] [Related]
2. [Suppression of immunological response by ascitic fluid from gastrointestinal cancer patients]. Amemiya K Nihon Geka Gakkai Zasshi; 1983 Dec; 84(12):1229-36. PubMed ID: 6201709 [TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Badger AM; Cooperband SR; Merluzzi VJ; Glasgow AH Cancer Res; 1977 Apr; 37(4):1220-6. PubMed ID: 139204 [TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids. Lu XG; Mao JS; Tong JF; Zhu L; Liu J; Gong XB; Huang J Int J Lab Hematol; 2007 Apr; 29(2):132-8. PubMed ID: 17474886 [TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Tamura K; Shibata Y; Matsuda Y; Ishida N Cancer Res; 1981 Aug; 41(8):3244-52. PubMed ID: 6166371 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive activity of peritoneal fluid in women with endometriosis. Oosterlynck DJ; Meuleman C; Waer M; Koninckx PR; Vandeputte M Obstet Gynecol; 1993 Aug; 82(2):206-12. PubMed ID: 8336865 [TBL] [Abstract][Full Text] [Related]
8. [Soluble factors with immunosuppressive activity in human neoplasms]. Baroni R; Guidi L; Bartoloni C; Gambassi G Minerva Med; 1988 Oct; 79(10):839-44. PubMed ID: 2460799 [TBL] [Abstract][Full Text] [Related]
9. Comparative study of alpha 1-acid glycoprotein molecular variants in ascitic fluid of cancer and non-cancer patients. Fujii M; Takahashi N; Hayashi H; Furusho T; Matsunaga K; Yoshikumi C Anticancer Res; 1988; 8(3):303-6. PubMed ID: 3389735 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive factors in ascites fluids from ovarian cancer patients. Fumita Y; Tanaka F; Saji F; Nakamuro K Am J Reprod Immunol (1980); 1984 Dec; 6(4):175-8. PubMed ID: 6528882 [TBL] [Abstract][Full Text] [Related]
11. [Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis]. Polterauer P; Legenstein E; Müller M Wien Klin Wochenschr; 1985 Apr; 97(9):417-20. PubMed ID: 2408389 [TBL] [Abstract][Full Text] [Related]
12. [Tissue polypeptide antigen in serum and tissue in patients with lung cancer]. Haga E Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Apr; 28(4):595-604. PubMed ID: 2170727 [TBL] [Abstract][Full Text] [Related]
13. [Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]. Matsushima M; Kuwabara T; Miyamae K; Hachiya A; Kawahara M; Fukasawa K; Yagishita T; Tajima M; Sawamura Y; Shirai M Hinyokika Kiyo; 1984 Jul; 30(7):869-75. PubMed ID: 6507205 [TBL] [Abstract][Full Text] [Related]
14. Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. Medoff JR; Clack VD; Roche JK J Immunol; 1986 Sep; 137(6):2057-64. PubMed ID: 3528293 [TBL] [Abstract][Full Text] [Related]
15. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]. Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Hess AD; Gall SA; Dawson JR Cancer Res; 1979 Jul; 39(7 Pt 1):2381-9. PubMed ID: 36225 [No Abstract] [Full Text] [Related]
17. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
18. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM; Southern JF; Warshaw AL; Lewandrowski KB Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126 [TBL] [Abstract][Full Text] [Related]
19. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]. Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169 [TBL] [Abstract][Full Text] [Related]
20. [Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]. Kanauchi M; Sawai F; Saito T; Yumura F; Kanauchi K; Hamaguchi T; Hara Y; Yoshimura K; Nishiura K; Dohi K Gan No Rinsho; 1984 Mar; 30(3):265-71. PubMed ID: 6201629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]